Matt Frieman returns to TWiV to discuss the COVID-19 pandemic from the point of view of a coronavirologist, including his work with Novavax on their spike protein-based vaccine.
In COVID-19 clinical update #52, Daniel Griffin reviews differences in attack rates between children and adults, J&J vaccine phase III data, G6PD deficiency and vaccines, NIH halts convalescent plasma trial, dexamethasone in hospitalized patients, data on tocilizumab, and long COVID in children.
Ginger Campbell joins TWiV to discuss palliative care for COVID-19 patients, and how to approach the disease from a goals of care perspective.
The entire TWiV team assembles to discuss resurgence of COVID-19 in Manaus, Brazil, discovery of SARS-CoV-2 related viruses in bats in Southeast Asia, and increased Ct values after administration of mRNA vaccine.
Paul Offit joins TWiV to discuss all things vaccine, including how COVID-19 vaccine development was accelerated, whether the vaccines are safe and efficacious, the difference between an EUA and a licensed vaccine, sterilizing immunity, herd immunity, and much more.
TWiV explores single dose administration and timing of second dose of AZD1222 COVID-19 vaccine, safety and efficacy of Sputnik V, and control of coronavirus recombination by a viral proofreading exonuclease.
On this episode, a discussion of why modifying the dose schedule of the mRNA vaccines in the US is not a good idea, evidence that lower Ct values on hospital admission is associated with higher mortality, and dose-dependent response to SARS-CoV-2 infection of ferrets.
The Hosts of TWiV
Vincent Racaniello, Ph.D.
Brianne Barker, Ph.D.
Rich Condit, Ph.D.
Alan Dove, Ph.D.
Daniel Griffin, M.D.,
Ph.D., CTropMed CTH
Angela Mingarelli, DVM
Jolene Ramsey, Ph.D.
Kathy Spindler, Ph.D.